Skip to main content
. 2021 Apr 28;12:659943. doi: 10.3389/fimmu.2021.659943

Figure 1.

Figure 1

Experimental design of the study. EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; Rifafour®, 150 mg rifampicin + 75 mg isoniazid + 400 mg pyrazinamide + 275 mg ethambutol; RH, rifampicin and isoniazid; N, number of mice; PT: post treatment; PI: post infection; AIN-93G formulation containing soybean oil at 70 g/kg diet and hydrogenated coconut oil at 30 g/kg diet and 8 g Fe/kg (40 ppm Fe); EPA/DHA supplemented diet contains soybean oil at 70 g/kg diet, coconut oil at 27 g/kg diet, Incromega TG4030 oil DHA 500 TG SR (minimum 44% of FA as EPA; minimum 28% of FA as DHA); untreated group received no treatment throughout the entire duration of the experiment.